OS Therapies commercial chief holds 25,000 shares

OS Therapies Inc Chief Commercial Officer Kerry M. Clem reported direct holdings on September 29, 2026, of 25,000 common shares and options covering 30,000 common shares.

Rhea-AI Filing Summary

OS Therapies Inc Chief Commercial Officer Kerry M. Clem reported direct holdings on September 29, 2026, of 25,000 common shares and options covering 30,000 common shares. The options have a $1.80 exercise price; they were granted October 21, 2025, vested in full April 21, 2026, and expire October 21, 2035. The common shares and options are listed as direct holdings.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Clem Kerry M

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
holding	Stock Options (right to buy) F1	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Options (right to buy) — 30,000 contracts (Direct); Common Stock — 25,000 shares (Direct)

Footnotes (1)

1. F1. On October 21, 2025, the reporting person was granted options to purchase 30,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vested in full on April 21, 2026.

Key Figures

Direct common shares: 25,000 shares Options covering common shares: 30,000 shares Exercise price: $1.80 per share +1 more

4 metrics

Direct common shares 25,000 shares Reported September 29, 2026

Options covering common shares 30,000 shares Reported September 29, 2026

Exercise price $1.80 per share Stock options

Expiration date October 21, 2035 Stock options

Key Terms

Stock Options (right to buy), stock option award agreement, vested in full

3 terms

Stock Options (right to buy) financial

"Stock Options (right to buy)"

stock option award agreement financial

"pursuant to the terms and conditions of a stock option award agreement"

A stock option award agreement is a legal document that gives a person the right to buy a company’s shares at a fixed price later, with clear rules about when those rights become usable, how long they last, and any conditions for exercising them. For investors it matters because these agreements can increase the total shares outstanding and affect company costs and incentives—like a coupon that can turn into new stock, changing ownership and future stock supply.

vested in full financial

"These options vested in full on April 21, 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many OSTX shares and options did Chief Commercial Officer Kerry M. Clem report?

Kerry M. Clem reported direct holdings of 25,000 common shares and options covering 30,000 common shares on September 29, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 04:50 PM Accepted by SEC EDGAR 10/05/2026 - 04:49 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Clem Kerry M

(Last) (First) (Middle)

C/O OS THERAPIES INCORPORATED

115 PULLMAN CROSSING ROAD, SUITE 103

(Street)

GRASONVILLE MARYLAND 21638

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/29/2026

3. Issuer Name and Ticker or Trading Symbol
OS Therapies Inc [ OSTX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	25,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	(1)	10/21/2035	Common Stock	30,000	$1.8	D

Explanation of Responses:

1. On October 21, 2025, the reporting person was granted options to purchase 30,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vested in full on April 21, 2026.

Remarks:

Exhibit 24: Power of Attorney

	/s/ Kerry M. Clem	10/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)